^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    HNRNPUL1 (Heterogeneous Nuclear Ribonucleoprotein U Like 1)

    i
    Other names: HNRNPUL1, Heterogeneous Nuclear Ribonucleoprotein U Like 1, E1B-AP5, E1BAP5, HNRPUL1, Heterogeneous Nuclear Ribonucleoprotein U-Like Protein 1, Adenovirus Early Region 1B-Associated Protein 5, E1B-55 KDa-Associated Protein 5, E1B 55kDa Associated Protein 5, FLJ12944
    Associations

    News

    Trials
    1m
    Multi-scale transcriptomics analysis reveals MHC suppression in MEF2D fusion positive B-cell acute lymphoblastic leukemia. (PubMed, Biochem Biophys Res Commun)
    ChIP-seq data of the Kasumi-7 cell line showed that the MEF2D::HNRNPUL1 fusion protein directly bound to the region next to an intronic enhancer sequence of CIITA, indicating a MEF2D-CIITA-MHC potential pathogenic mechanism. This study offers a comprehensive analysis of MEF2D-fusion cases, detailing the fusion features and functional alterations, thus providing insights for future investigations.
    Journal
    |
    MEF2D (Myocyte Enhancer Factor 2D) • HNRNPUL1 (Heterogeneous Nuclear Ribonucleoprotein U Like 1)
    1m
    BET bromodomain inhibition: a potential therapeutic avenue in MEF2D-HNRNPUL1-rearranged B-cell acute lymphoblastic leukaemia. (PubMed, Leuk Lymphoma)
    A novel finding is that BET inhibitor induces DNA damage by downregulating DNA repair genes. These findings highlight that anti-leukemic activity of BET inhibitors offers a promising strategy to improve outcomes in this high-risk leukemia subtype.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BRD4 (Bromodomain Containing 4) • MEF2D (Myocyte Enhancer Factor 2D) • HNRNPUL1 (Heterogeneous Nuclear Ribonucleoprotein U Like 1)
    5ms
    Identification of novel gene fusions in high-grade serous ovarian carcinoma: implications for tumorigenesis and targeted therapy. (PubMed, Cancer Genet)
    This study identified candidate driver fusion genes and suggested new therapeutic targets for HGSOCs.
    Journal
    |
    ER (Estrogen receptor) • TP53 (Tumor protein P53) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • AXL (AXL Receptor Tyrosine Kinase) • HDAC1 (Histone Deacetylase 1) • CAMK2D (Calcium/Calmodulin Dependent Protein Kinase II Delta) • LATS1 (Large Tumor Suppressor Kinase 1) • PSMD1 (Proteasome 26S Subunit Non-ATPase 1) • BMPR1A (Bone Morphogenetic Protein Receptor Type 1A) • CAMKK1 (Calcium/Calmodulin Dependent Protein Kinase Kinase 1) • HNRNPUL1 (Heterogeneous Nuclear Ribonucleoprotein U Like 1) • SH3PXD2A (SH3 And PX Domains 2A) • YY1 (YY1 Transcription Factor) • ZNF143 (Zinc Finger Protein 143)
    |
    TP53 mutation
    7ms
    Hsa_circ_0013729 Promotes Gastric Cancer Progression by Regulating MEF2D in ceRNA- and RBP- Dependent Manners. (PubMed, Biochem Genet)
    Hsa_circ_0013729 acted as a ceRNA for miR-361-3p and interfered with the binding between miR-361-3p and MEF2D. Hsa_circ_0013729 interacted with HNRNPIL1 to stabilize MEF2D mRNA.Hsa_circ_0013729 may promote gastric cancer via the miR-361-3p/MEF2D axis and HNRNPUL1/MEF2D axis, showing potential as a biomarker and therapeutic target.
    Journal
    |
    PTBP1 (Polypyrimidine Tract Binding Protein 1) • MEF2D (Myocyte Enhancer Factor 2D) • MIR361 (MicroRNA 361) • HNRNPUL1 (Heterogeneous Nuclear Ribonucleoprotein U Like 1)
    7ms
    Molecular mechanisms of unique therapeutic potential of CUDC-907 for MEF2D fusion-driven BCP-ALL. (PubMed, Signal Transduct Target Ther)
    Furthermore, this compound's effectiveness and safety were confirmed in both MH/NRASG12D BCP-ALL mouse model and MB patient-derived xenograft (PDX) model, outperforming conventional therapies. These results support the therapeutic potential of dual-pathway inhibition in MEF2D fusion (+) BCP-ALL and suggest CUDC-907 as a promising candidate for precision treatment in fusion-driven leukemias with similar molecular dependencies.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • MEF2D (Myocyte Enhancer Factor 2D) • BCL9 (BCL9 Transcription Coactivator) • HDAC9 (Histone Deacetylase 9) • HNRNPUL1 (Heterogeneous Nuclear Ribonucleoprotein U Like 1)
    |
    NRAS G12
    |
    fimepinostat (CUDC-907)
    over1year
    GALNT14-mediated O-glycosylation drives lung adenocarcinoma progression by reducing endogenous reactive oxygen species generation. (PubMed, Cell Signal)
    Mechanistically, GALNT14 reduced the accumulation of endogenous reactive oxygen species (ROS) to exert its oncogenic function via O-glycosylating hnRNPUL1 to upregulate AKR1C2 expression. Meanwhile, GALNT14 expression was directly modulated by miR-125a.These findings indicated that GALNT14-mediated O-GalNAcylation could drive LUAD progression via eliminating ROS and might be a valuable therapeutic target.
    Journal
    |
    AKR1C2 (Aldo-Keto Reductase Family 1 Member C2) • HNRNPUL1 (Heterogeneous Nuclear Ribonucleoprotein U Like 1) • MIR125A (MicroRNA 125a)
    over1year
    LINC00461 promotes bladder cancer cells EMT through miR-518b/HNRNPUL1 axis. (PubMed, Discov Oncol)
    Moreover, we found that LINC00461 regulated HNRNPUL1 expression through miR-518b sponge activity, and the miR-518 inhibitor could reverse the inhibitory effects of LINC00461 knockdown on BC cell proliferation, migration, and EMT. Our results suggest that LINC00461 may serve as a potential biomarker and therapeutic target for BC.
    Journal
    |
    HNRNPUL1 (Heterogeneous Nuclear Ribonucleoprotein U Like 1) • LINC00461 (Long Intergenic Non-Protein Coding RNA 461)
    over1year
    The Molecular and Biological Function of MEF2D in Leukemia. (PubMed, Adv Exp Med Biol)
    The MEF2D-CEBPE axis is highlighted as a key transcriptional mechanism controlling the block of leukemic cell self-renewal and differentiation in AML. This chapter starts with the structure and function of MEF2 family proteins, specifically summarizing and analyzing the role of MEF2D in B-ALL and AML, mediating the complex molecular mechanisms of transcriptional regulation and exploring their implications for human health and disease.
    Journal
    |
    IRF8 (Interferon Regulatory Factor 8) • CSF1R (Colony stimulating factor 1 receptor) • BRD4 (Bromodomain Containing 4) • MEF2C (Myocyte Enhancer Factor 2C) • MEF2D (Myocyte Enhancer Factor 2D) • SS18 (SS18 Subunit Of BAF Chromatin Remodeling Complex) • ZMYND8 (Zinc Finger MYND-Type Containing 8) • BCL9 (BCL9 Transcription Coactivator) • HNRNPUL1 (Heterogeneous Nuclear Ribonucleoprotein U Like 1)
    over1year
    Hepatocellular carcinoma: An analysis of the expression status of stress granules and their prognostic value. (PubMed, World J Gastrointest Oncol)
    Based on the impact of SG genes on HCC prognosis, in the future, it will be used as a biomarker as well as a unique therapeutic target for the identification and treatment of HCC.
    Journal
    |
    BICC1 (BicC Family RNA Binding Protein 1) • DKC1 (Dyskerin Pseudouridine Synthase 1) • DDX1 (DEAD-Box Helicase 1) • HNRNPUL1 (Heterogeneous Nuclear Ribonucleoprotein U Like 1)
    over1year
    Genetic and clinical characteristics of acute B-cell lymphoblastic leukemia with MEF2D fusions and report of two novel MEF2D rearrangements. (PubMed, Ann Hematol)
    The median overall survival of these patients was only 11 months. This small cohort showed a high incidence of early relapse and short survival in patients with MEF2D rearrangements.
    Journal
    |
    ARID1B (AT-Rich Interaction Domain 1B) • MEF2D (Myocyte Enhancer Factor 2D) • BCL9 (BCL9 Transcription Coactivator) • HNRNPUL1 (Heterogeneous Nuclear Ribonucleoprotein U Like 1)
    almost2years
    AKAP8 promotes ovarian cancer progression and antagonizes PARP inhibitor sensitivity through regulating hnRNPUL1 transcription. (PubMed, iScience)
    In addition, AKAP8 modulates PARP1 expression through hnRNPUL1, and AKAP8 inhibition enhances PAPR inhibitor cytotoxicity in ovarian cancer. Together, our study uncovers the crucial function of AKAP8 condensation-mediated transcription regulation, and targeting AKAP8 could be potential for improvement of ovarian cancer therapy.
    Journal • PARP Biomarker
    |
    HNRNPUL1 (Heterogeneous Nuclear Ribonucleoprotein U Like 1)
    2years
    Development of a Targeted NGS Panel for Hematologic Malignancies According to Who/ICC 2022 Guidelines (ASH 2023)
    The old targeted DNA/RNA NGS panel was successfully updated according to the 2022 WHO and ICC guidelines, and can be used to accurately and efficiently detect the genetic variants of blood cancers.
    Next-generation sequencing
    |
    FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • CDK6 (Cyclin-dependent kinase 6) • NSD1 (Nuclear Receptor Binding SET Domain Protein 1) • HOXA9 (Homeobox A9) • P2RY8 (P2Y Receptor Family Member 8) • CBFA2T3 (CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3) • CDX2 (Caudal Type Homeobox 2) • GLIS2 (GLIS Family Zinc Finger 2) • KAT6A (Lysine Acetyltransferase 6A) • KDM5A (Lysine Demethylase 5A) • TAF15 (TATA-Box Binding Protein Associated Factor 15) • BCL11B (BAF Chromatin Remodeling Complex Subunit BCL11B) • NUTM1 (NUT Midline Carcinoma Family Member 1) • ZBTB16 (Zinc Finger And BTB Domain Containing 16) • ZEB2 (Zinc Finger E-Box Binding Homeobox 2) • BCORL1 (BCL6 Corepressor Like 1) • ENAM (Enamelin) • HNRNPUL1 (Heterogeneous Nuclear Ribonucleoprotein U Like 1) • PRDM16 (PR/SET Domain 16) • PRPF8 (Pre-MRNA Processing Factor 8)